cyrilzakka/clinical-trials huggingface dataset:
Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma

This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin. It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has been previously treated with chemotherapy.

Nasopharyngeal Cancer (NPC) is one of the common cancer in Southeast Asia. In this region NPC is associated with Epstein Barr Virus (EBV) chronic infection with EBV DNA identifiable in almost all the NPC tumors and patient's serum at the time of diagnosis. Chinese, especially cantonese has the highest incidence. Only about 30% of patients presents early disease and has a good treatment outcome (80% cure for stage I disease and 70% for stage II by radiation).

This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin. It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has been previously treated with chemotherapy.

Investigators believe EBV infection is necessary to cause NPC and that EBV DNA levels in the blood may directly relate to the total size of the tumor. Because NPC patients in this situation have a poor outlook, we design this study to evaluate the combination of Ifosfamide and doxorubicin for further treatment. While this combination of medicines has been used in many other forms of cancer, it has not been tested in patients with NPC.

Eligibility Criteria:
Inclusion Criteria:

* Histological diagnosis of NPC
* Age \> 18 years old
* Measurable metastatic or recurrent disease (s)
* Received one prior chemotherapy regimen for metastatic or recurrent NPC which relapsed or became refractory before entry.
* ECOG PS 0, 1 or 2
* WBC \> 3,500/uL and ANC \> 1,500/uL Platelet \> 100,000/uL Creatinine - within normal limits SGOT \< 3 X UNL Bilirubin \< 2.0 mg/dL
* Ejection fraction \> 45% and no history of myocardial infarction or congestive heart failure in the last 6 months. No history of cardiac ventricular arrythmia or ventricle tachycardia, or uncontrolled atrial fibrillation or supraventricular tachycardia with hemodynamic compromising status.
* Random blood glucose level \< 250 mg
* Signed informed consent

Exclusion Criteria:

* Received more than one prior chemotherapy for metastatic or recurrent disease
* Ejection fraction \< 45%
* WBC \< 3,500/UL or ANC \< 1,500/UL or P/t \< 100,000/UL or SCOT\> 3 x UNL or Bilirubin \> 2.0 mg/dL or Creatinine \> UNL
* ECOG PS \> 3
* Hx of myocardial infarction within last 6 months
* Random blood glucose level less than or equal 250 mg
Outcome of Radiation Therapy in Urinary Bladder Squampus Cell Carcinoma

Detection of distribution of clinico-pathological features of squamous cell carcinoma of urinary bladder and their relation to treatment outcome.


Eligibility Criteria:
Inclusion Criteria:

1. age 18-70 .
2. histologically proved urinary bladder squamous cell carcinoma.
3. non-metastatic disease.
4. all patients who underwent radical treatment or bladder preserving approach.
5. patient with isolated urinary bladder carcinoma (no other or previous primary).

Exclusion Criteria:

1. age \< 18 , \> 70.
2. patient not documented having bladder squamous cell carcinoma by biopsy (cystoscopic or operative).
3. metastatic disease.
4. patient with synchronous or metachronous double primary
The Involvement of Breast Cancer Patients During Oncological Consultations

The main aim of the study is to assess if a pre consultation intervention facilitates greater participation of patients (and accompanying key persons when present) in the consultation process by determining an increase in questioning and/or in the number of different illness related issues (e.g. diagnosis, treatment, prognosis) being discussed with the oncologist.

Other aims are to assess the effect of the intervention on the oncologist's level of patient involvement, on patient satisfaction and coping and to explore the role of key persons accompanying the patient.

The investigators expect that patients who have the opportunity to rehearse their informative needs before the consultation will ask a greater number of questions which in turn will determine their greater involvement by the physician and a greater number of satisfied needs. The investigators expect also that the straightforward use of a list of printed questions of potential relevance for cancer patients and their companions at an early stage of illness, by modifying the process of information exchange, increases their participation and satisfaction with the consultation, with potential benefits for treatment adherence and consequently treatment efficacy.


Eligibility Criteria:
Inclusion Criteria:

* all consecutive patients
* age between 18 and 75 years
* attending the Oncology Out-patient Clinics of the participating centres
* recent diagnosis of breast cancer at an early stage

Exclusion Criteria:

* presence of metastasis or relapse
* severe mental deterioration
* comprehension difficulties of the Italian language.
HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

This is a multi-site, open-label non-inferiority study of the 9vHPV vaccine among a population of children, adolescents and young women living with HIV in Eswatini. This protocol seeks to assess immunogenicity of a two-dose 9vHPV vaccine regimen among girls and boys (9-14 years) and young women (15-26 years) living with HIV on antiretroviral therapy versus a three-dose 9vHPV vaccine regimen among HIV uninfected young women (15-26 years) in Eswatini. The secondary objectives include examining the safety profiles of the two-dose 9vHPV regimen in those living with HIV and the three-dose 9vHPV regimen in HIV-uninfected young women, as well as measuring the completion of the vaccination series among those living with HIV and those who are not infected with HIV.

Cervical cancer remains a significant threat to public health worldwide and remains the leading cause of cancer-associated mortality in women in Sub Saharan Africa. Cervical cancer-associated morbidity and mortality is preventable through HPV vaccination, and screening and treatment of pre-cancerous lesions. To date, there is no nationwide HPV vaccination program in Eswatini and the country is not eligible for Global Alliance for Vaccines and Immunization (GAVI) procurement of HPV vaccines, and yet the triad of HIV, sexually transmitted infections (STI) and cervical cancer generates a severe disease burden warranting immediate introduction of this intervention. Given the global limitations in vaccine supply and the high cost for procurement, country programs, including in Eswatini, must optimize vaccine resources in order to maximize HPV vaccine coverage.

Eligibility Criteria:
Inclusion Criteria:

For people living with HIV receiving two-dose regimen:

* Females 9-26 years and males 9-14 years,
* Documented HIV infection,
* Aware of HIV+ status,
* Currently receiving antiretroviral treatment (ART) for HIV infection for at least six months,
* Living in Eswatini,
* For individuals 18+ years: able to provide informed consent,
* For individuals 15-17 years: able to provide informed assent,
* For individuals 9-14 years of age: able to provide informed assent AND accompanied by an adult caregiver who is able to give informed consent,
* Intending to remain in the vicinity of the study sites for the study period

For reference group of HIV-uninfected women receiving three-dose regimen:

* Females 15-26 years,
* Documented negative HIV test at baseline
* Living in Eswatini,
* Able to provide informed assent (15-17 years) or informed consent (18-26 years)
* Intending to remain in the vicinity of the study sites for the study period

Exclusion Criteria:

For all participants:

* Diagnosis of other immunosuppressive diseases or receipt of immunosuppressive medications,
* Diagnosis of other acute or chronic illness,
* Receipt of other vaccinations within 2-3 weeks before or after study vaccination,
* Receipt of blood-derived products within 6 months before or during the study,
* Previous receipt of an HPV vaccine,
* Currently pregnant,
* Known allergies to a vaccine component
Diffusion Weighted Magnetic Resonance Imaging in Chronic Kidney Disease

Chronic kidney disease (CKD) is a common global public health problem and the average incidence of end-stage renal disease in developing countries is 150 per million population, which is lower than that in the developed world

Since renal parenchymal disease is accompanied by renal dysfunction, monitoring renal function permits assessment of disease progression, and periodic assessment of renal function is necessary for optimal management of a patient with suspected/proven renal disease. Serum creatinine (S Cr), blood urea (BU), and estimated glomerular filtration rate (eGFR) derived from creatinine clearance are useful for monitoring renal function; however, these indirect measures of renal filtration are imperfect and cannot assess single kidney function.

Keeping in view the limitations of serum markers, imaging may play an important role in the evaluation of renal parenchymal disease. Ultrasonography (US) and computed tomographic (CT) scan provide good anatomic images but limited functional information. Although US may show changes in renal echogenicity, it suffers from operator dependency and lacks objectivity. In addition to exposure to ionizing radiation, computed tomography (CT) scan requires use of iodinated contrast material, which is undesirable in patients with renal dysfunction. Magnetic resonance imaging (MRI) has the unique ability to show both structure and function objectively without any radiation exposure to the patient. Functional MRI techniques such as diffusion-weighted imaging (DWI), blood oxygen level-dependent (BOLD) imaging have potential utility in the evaluation of renal function .

Eligibility Criteria:
Inclusion Criteria:

* Patients in different age and sex groups with CKD detected by clinical and laboratory examination.

Exclusion Criteria:

* Patients with any general contraindication to MRI as presence of any paramagnetic substance as pacemakers or in severely ill patients or those with claustrophobia and arrhythmic patients.
Feasibility of a Method for Analysis of Alzheimer´s Disease Specific Proteins in Nasal Secretion

This study is a first in man study investigating the feasibility of the collection, storage, processing and analysis of 4 key biomarkers for the diagnosis of Alzheimer's disease \[AD\] in nasal secretion. Nasal secretion \[NS\] constitutes a minimally invasive access to cerebrospinal fluid \[CSF\]. Therefore, it could be highly suitable for detection and monitoring of the AD relevant biomarkers pTau181, total Tau, Amyloid-ß1-40 and Amyloid-ß1-42. This study evaluates correlations of biomarker patterns in NS and CSF. Furthermore, the correlations of the 4 AD specific biomarkers in nasal secretion and CSF is investigated. For this study, patients with cognitive impairment (AD and NonAD group) and healthy controls were included.


Eligibility Criteria:
Inclusion Criteria:

* Group A Patient WITH cognitive impairment and no nasal pathologies. CSF analysis is planned or results are already available
* Group B Patient WITHOUT cognitive disorder and without pathologies in the nasal area

Exclusion Criteria:

* Presence of an obstructing nasal cavity disease
* Patient suffers from an acute upper respiratory tract infection (putrid rhinorrhea)
* Inability to give consent
Ultrasound Guided Versus Palpation Guided Cricothyrotomy With Poorly Defined Anatomical Landmarks

Inability to provide oxygen to the patient remains the most fearful anesthesia-related mishap. Cricothyrotomy (CT) is an infrequently performed but life saving procedure for an anesthesiologist, who is encountered with this situation. The current method of cricothyrotomy relies on digital palpation (DP). Several patient populations, including morbidly obese, short neck, radiation to and previous neck surgeries, have difficult landmarks for this procedure. Ultrasound (US) technology has been used in the past to visualize landmarks for cricothyrotomy, but there is no study which has examined the role of ultrasound in patients who have obscure landmarks. There is no data related to the performance of ultrasound guided cricothyrotomy in these patients. In this study, we aimed to determine the outcomes of CT performed on human cadavers using US-guidance, compared to conventional DP, of anatomical landmarks. In particularly, complication rates, failure to cannulate, correct placement of the device and insertion time of CT were assessed.

For each cadaver - epidemiological data (age, sex) and morphometric data (Body Mass Index, neck circumference, thyromental distance)

The primary outcome measure was the complication rate as assessed by the severity of injuries; defined as the incidence and severity of posterior laryngeal and tracheal wall injuries, as graded by two anesthesiologists using the grading system described by Murphy et al,( none (no injury); mild (\< 5 mm laceration); moderate (\> 5mm laceration or partial puncture); severe (\> 10 mm laceration or full puncture)). For clinical relevance and analysis of data we dichotomized the scale to none-mild and moderate - severe injuries.

The secondary outcomes include: 1) insertion time, measured in seconds (s) from the time of palpation of the skin to insertion of the Portex device in the trachea; 2) failure, with a 'failure' defined as any attempt in which the trachea was not cannulated, or which required \> 300 s to perform; and 3) correct land-marking, defined as having the Portex device inserted via the CM.

Eligibility Criteria:
Inclusion Criteria:

* Residents who are novice to the application of ultrasound in difficult airway scenarios
* Cadavers with difficult and imposible landmarks identification

Exclusion Criteria:

* Anethesiologist with previous experience in CT, manual or ultrasound assisted
* Patients with easily identifiable landmarks
Facial Thermography Study of Levocetirizine Versus Cetirizine

Phase IV, human pharmacology, exploratory, randomized, 3-way (3 treatment periods) cross-over, double blind, double dummy, placebo controlled study to compare levocetirizine and cetirizine by means of IR thermography.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male Caucasian subject aged between 18 and 55 years (both inclusive).
* Subject must have a positive prick test to histamine (wheal diameter ≥ 6 mm with histamine dihydrochloride (100 mg/mL) and ≤ 3 mm with diluent control).

Exclusion Criteria:

* History of allergic disease, documented or suspected, including but not limited to: asthma, whether or not considered as allergic; nocturnal cough episode suspected to be of asthma-equivalent nature (three or more consecutive nights resulting in sleep disturbances) ; allergic rhinitis, conjunctivitis or sinusitis; nasal polyposis; dermatitis of the face or neck; drug or food allergy.
* Any clinically significant vascular disease such as hyper- or hypotension, venous disorder, vasculitis etc.
* History of hot flushes and any other vasomotor disorders.
* ENT infection or Upper Respiratory Tract Infection not completely cured at least one week before inclusion.
* Any known history of laryngeal edema.
* Nasal structural abnormalities (e.g. deviation of the nasal septum...).
* Recent immunotherapy
* Skin irritants or UV exposure 48 hours before each visit.
Effectiveness and Cost-effectiveness of Telephone-delivered Psychotherapy for Depression in Primary Care

The aim of the study is the examination of effectiveness and cost-effectiveness of a telephone-based psychotherapy (Tel-PT) for depression compared to treatment as usual in primary care.

The overall purpose of the study is to examine the effectiveness of telephone psychotherapy (Tel-PT) for the treatment of mild to moderate depression on different outcome-levels and under clinically representative conditions in Swiss primary health care. The randomized-controlled trial (RCT) will evaluate the primary hypothesis that Tel-PT is more effective than routine primary care (i.e. treatment as usual, TAU), more specifically, that it leads to significant higher reduction in depression severity than TAU at follow-up.

The intervention group (IG) receives a manualized short-term cognitive behavioral treatment, which is the adapted German version of the program "Creating a balance" developed in the USA. The therapy consists of one face-to-face and 8-12 telephone contacts and is carried out by a licensed psychotherapist.

More concrete, recruitment and inclusion of the patients will be carried out by the participating general practitioners (GPs). GPs will be instructed to screen patients at risk for depression, especially those revealing diffuse somatic symptoms and suffering from chronic diseases. If positively screened, patient's depressive symptoms are assessed with Patient Health Questionnaire (PHQ-9) and diagnosed according to ICD-10.

All GPs will receive an initial training prior to their participation, providing them with study information and procedures as well as training in screening procedure, psychodiagnostics and study enrolment.

Eligible patients are provided with detailed study information and asked to participate. Subsequently, patients will give informed consent. Patients will then be included into the study and fill out the baseline questionnaires (t0). After that, randomization will be carried out at the University of Zurich, based on an appropriately created computer algorithm. Both GPs and patients are informed about the results by the study team within two days. Subsequently, patients in control group (CG) will receive regular text messages and patients in the intervention group (IG) will be called by the study therapist to schedule an initial appointment.

In case of positive results, the overarching objective is the optimization of mental health services for depressed patients by implementing an evidence-based, accessible and cost-effective treatment option into primary care.

Eligibility Criteria:
Inclusion Criteria:

* PHQ-9 score of \> 5 and ≤15.
* Informed Consent as documented by signature (Appendix Informed Consent Form)
* Minimum age of 18 years
* Diagnosis of mild to moderate depression according to ICD-10 (F32.0, F32.1, F33.0, F33.1)

Exclusion Criteria:

* Patients currently being in psychotherapeutic treatment or treatment in past three months
* Suicidal tendencies or suicidality
* Insufficient knowledge of German language
* Health condition that does not allow questionnaire completion
C-MAC Blade D Video Vs Macintosh Laryngoscope for Double Lumen Tube Insertion

The goal of this clinical trial is to know which type of laryngoscope is better for Double Lumen Tube (DLT) insertion, in participants undergoing elective thoracic surgeries.

The main question aim to answer is Is C-MAC blade D video laryngoscope better than Macintosh laryngoscope for DLT insertion in term of time taking for intubation and hemodynamic changes to laryngoscopy? Researchers are comparing two groups of participants

* Participants in Group A are receiving intubation from C-MAC blade D video laryngoscope.
* Participants in Group B are receiving intubations from Macintosh laryngoscope.

Double Lumen Tube (DLT) is a common airway management device, used to implement lung isolation technique during thoracic surgeries. Intubation of DLT is challenging because it is much larger in diameter and rotational insertion technique is associated with significant risk of prolong intubation, intubation failure, greater hemodynamic changes and airway trauma.

Objective of this study is to compare the outcome C-MAC blade D video laryngoscope and Macintosh laryngoscope for DLT insertion, in term of time taking for DLT intubation and hemodynamic changes to laryngoscopy.

This study is conducting at Department of Anesthesiology at SMBBIT, Pakistan. Data is collecting after taking approval from Ethical Review Committee and written informed consent from participants.

Participants are enrolling by primary investigator, day before surgery. All participants are undergoing simple randomization by lottery method.

During induction of aesthesia, time for intubation is noting from introduction of the laryngoscope blade till three complete capnograph cycles.

Participants have also been assessed for hemodynamic parameters {Heart Rate (HR), Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP)} to intubation at 0 (Baseline), 1st Minute , 3rd Minute and 5th Minute after intubation.

After Completing data collection, Data analysis will be done by using SPSS version 26.

Eligibility Criteria:
Inclusion Criteria:

* Mallampati 1 and 2.
* ASA 1 and 2.
* Patients who will be prepared for elective thoracic surgeries under general anesthesia.

Exclusion Criteria:

* Pregnant Patients.
* Patients with anticipated difficult airway.
* Patients with limited neck extension.
* Thyromental distance less than 6.5cm.
* BMI greater than 35. (Weight in kilogram (kg) divided by height in meters squared)
* Patients at a risk of aspiration.
* Failure to intubate the patient after 3 attempts.
Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging

Huntington's disease is a rare genetic neurodegenerative disease. It is accompanied by movement disorders, cognitive and behavioral. The social behavior of patients are changed, affecting interpersonal relationships. Patients with Huntington's disease are described as self-centered, lacking sympathy and empathy and mentally inflexible. These behavioral problems can be a major source of anxiety for patients and their families. These disorders also have a negative impact cognitive and motor symptoms as well as the functional abilities and the quality of life of patients and their entourage. Authors have suggested that these problems could be related inter alia to social cognition disorders. This concept refers to a set of skills and emotional and social experiences that regulate relations between individuals and can explain the behavior of individuals and groups. The objective is to evaluate disorders of social cognition, which may account for behavioral changes in Huntington's disease.


Eligibility Criteria:
Inclusion Criteria:

For all particpipants

* Patient gave its written consent
* between 20 and 70 years
* School level : at least 7 years
* native language: french

For presymptomatic patient

* Huntington's disease diagnosed with abnormal number of CAG repeats: 36 \< nucleotide expansion (CAG)
* Unified Huntington Disease Rating Scale moteur ≤ 5

For symptomatic patient

* Huntington's disease diagnosed with abnormal number of CAG repeats: 36 \< nucleotide expansion (CAG)
* Unified Huntington Disease Rating Scale moteur \> 5

Exclusion Criteria:

* No national health insurance affiliation
* Being under guardianship
* Meeting brain MRI exclusion criteria (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body, Renal failure, hypersensitivity of Gadolinium) or refusing MRI
* Pregnant or lactating women
* Patient with involuntary movement hampering the realization of MRI